Background: Non-coeliac gluten-sensitivity (NCGS) has been proposed as a new en-
likely not the only substance generating symptoms. 2 The literature suggest that it is a multifactorial process involved in the development of NCGS, and promote both gluten, fermentable oligo-, di, monosaccharides and polyols (FODMAPs) and amylase-trypsin inhibitors (ATIs) as possible triggers.
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The last decade the avoidance of wheat and other gluten-like containing grains has increased all over the world, with the highest prevalence in the western countries. 6 The decline in wheat intake can arguably be due to the fact that ingestion of gluten has been linked to a wide range of clinical disorders like gastrointestinal symptoms and abdominal pain, skin lesions, migraines, weight gain, fatigue and depression. 7 The spectre of gluten-related disorders involves the three main groups CD, WA and NCGS. 8 The identification and diagnosis of both CD and WA is relatively easy due to the presence of known biomarkers, clinical history and specific examinations and tests. 9 NCGS, on the other hand, is still mainly a diagnosis based on exclusion of other diagnoses, given the lack of known biomarkers. The mechanisms causing the condition are unknown, and it is a subject of discussion whether gluten is the real problem for this group of patients. 3, 10 Common symptoms reported in NCGS are the same of those seen in patients with irritable bowel syndrome (IBS), typically gastrointestinal symptoms such as abdominal pain and bloating, altered bowel habits (diarrhoea, constipation or mixed form), nausea and regurgitation, and extra-intestinal symptoms including headache, fibromyalgia, fatigue, anxiety, foggy mind, joint pain, disturbed sleep pattern, weight gain, depression, skin rash, and dermatitis. 11, 12 To receive the NCGS diagnosis, the patient has to undergo a double-blind placebo-controlled food challenge (DBPCFC), and be able to correctly identify the gluten provocations from the placebo provocations due to a symptomatic relapse. However, symptoms during provocations are not necessarily measured when using a DBPCFC in the clinic, thus a positive result can be potentially by chance. 11 The aims of our study were (i) to investigate whether a doubleblind oral gluten challenge is capable of identifying the group of patients that can be correctly diagnosed with NCGS due to a symptomatic relapse in accordance with gluten, from all those patients reporting an improvement of symptoms while on a GFD, and (ii) to evaluate whether we could find a symptomatic difference between provocations with gluten and placebo.
| MATERIAL S AND ME THODS

| Participants
Twenty voluntary patients (14 female/6 male, aged 21-62 years) with suspected NCGS, and on a GFD, were recruited in the trial between February 2016 and January 2017. The recruitment of patients with a suspected reaction to gluten was done according to a list of patients who already had met either a gastroenterologist or a registered dietitian at the outpatient clinic at the Section of gastroenterology at
Haukeland University Hospital, Bergen, Norway, due to gastrointestinal and/or extra-intestinal symptoms related to food intake (most often bloating, flatulence, altered bowel habits, tiredness, headache, and muscle pain). All participants had experienced relief of symptoms while eating a gluten-free diet. Everyone had completed gastroscopy with duodenal biopsies and blood tests (coeliac serology and specific IgE against wheat and wheat components) within the last year. CD was excluded by duodenal biopsies, according to Marsh-Oberhuber classification. We excluded patients diagnosed with CD, WA, inflammatory bowel disease, IBS and lactose intolerance, ongoing infection, use of immune suppressive drugs and pregnant or lactating women. The participants had to be on a GFD for at least 6 weeks before inclusion. All participants reported a relief of symptoms while following a GFD. The compliance to the GFD was assessed by a 3-day food record prior to inclusion and a thorough interview at the baseline meeting by a registered dietitian.
| Study protocol
The study was a double-blind, randomized and placebo-controlled food challenge (DBPCFC). All patients were followed up for 4 weeks, and went through four periods (of 4 days) of double-blind provocation with gluten/placebo. The patients were given four packages of a standardized chocolate-muffin-mixture. The muffins were thoroughly tested for taste and appearance in a taste-lab, and all content besides gluten were similar in the two mixes (Ingredients: Sugar, wheat starch (gluten-free), fat reduced cocoa, rice flour, egg, potato starch, rising agent (disodium diphosphate, sodium hydrogen carbonate, calcium phosphate), rapeseed oil, salt, vanillin, and gluten isolate (in the gluten muffins)). The gluten added in the gluten-containing muffin was 100% pure gluten isolate extracted from wheat flour, in a dose of 5.5 g per muffin. The gluten isolate was analyzed and contained 78% protein, 3% fat, 10% carbohydrates, 0.5% fiber, and 8%
water. The muffin-mix was not analysed for total FODMAP content, but all ingredients are listed as low-FODMAP. It was not possible to
Key Points
• Non-coeliac gluten sensitivity (NCGS) has been proposed as a new entity with unknown prevalence and mechanisms, and there is a need for a standardized procedure to confirm the diagnosis.
• In a randomized, double-blind placebo-controlled challenge with gluten we found no specific effect of gluten in a group of patients with suspected NCGS.
• Gluten might not be the substance generating symptoms in this patient group and further research should investigate the effect of FODMAPs (fructanes), amylase-trypsin-inhibitors and the relationship between IBS and NCGS.
separate the mix with and without gluten by packing, appearance, consistency or taste ( Figure 1 ).
The patients randomly received two packages with gluten and two packages with placebo, in an order blinded for both patients and the researcher. They were instructed to bake out a new package of muffin-mix each week, for 4 weeks. Two muffins a day contain 11 g of gluten, and this amount is assumed to give adequate exposure of gluten compared to normal gluten intake in persons eating a glutencontaining diet. 1 After eating two muffins a day for 4 days, 3 days of wash-out (WO) followed. All participants were eating two muffins a day Monday to Thursday, then Friday to Sunday constituted the WO period before a new round started again the following Monday.
This was repeated for 4 weeks. The patients were followed up consecutively during the study period, through an interview after each provocation period where the compliance for muffin consumption were evaluated. All patients were instructed to maintain their usual, gluten-free diet throughout the study. The study design is presented in Figure 2 .
The study protocol was approved by the Regional Committees for
Medical and Health Research Ethics of West Norway (2015/1163).
Participation was voluntary, and all participants provided written consent in prior to study commencement.
| Symptom assessment
Changes in symptom severity during provocation were assessed by using two validated symptom questionnaires for irritable bowel syndrome (IBS); IBS-Symptom Severity Scale (IBS-SSS) and IBSSymptom Questionnaire (IBS-SQ). [13] [14] [15] IBS-SSS consists of five items (severity of abdominal pain, frequency of abdominal pain severity of abdominal distention, dissatisfaction with bowel habits and interference with life in general) measured by a 100-point Visual Analogue
Scale (VAS).
The IBS-SQ assesses six different symptoms: nausea, flatulence, stomach pain, constipation, diarrhea, and anorexia. Each symptom is ranged on a scale from 0 to 10 according to severity, of which 0 is no symptom and 10 is severe. The maximum score is 60, and a score ≥15
is regarded as active symptoms in a patient with IBS. 15 In addition to IBS-SSS and IBS-SQ the participants were asked ten additional questions also measured by 100-points VAS, including nausea and/or vomiting, early satiety, headache, backache, tiredness, belching and/or passing gas, heartburn, frequent or sudden urge to urinate, pain in thighs and pain on muscles and joints.
Both IBS-SSS, IBS-SQ and the 10 additional questions were filled out by the participants at baseline (the morning of the first day of provocation, before eating the first muffin) and after provocation (the evening of day 4 of provocation, after eating the last muffin in the current round). Symptom changes were measured as the difference between the baseline scores and the after-provocation scores.
A simple form, listing the four different provocation periods, was used to evaluate the endpoint assessing whether the patients correctly identified the periods with gluten exposure. After finishing all the provocation periods the patients were instructed to identify the two periods they believed they received gluten.
| Fatigue and quality of life
In addition to the implemented symptom questionnaires, the participants answered validated questionnaires evaluating quality of life and fatigue at baseline and end-point. Short Form of
The double-blind placebo controlled gluten provocation was performed using standardized chocolatemuffin-mixes (F) existing in identical versions containing gluten (B+E+C1) and placebo (A+D+C2). The muffins were identical in content except the gluten, and similar in looks, taste, and texture. The patients went through four provocation periods of for days, eating two muffins a day (11 g gluten or 0 g gluten), followed by 3 days' wash-out before the next provocation
the Nepean Dyspepsia Index (SF-NDI) and Fatigue Impact Scale (FIS) were used to evaluate quality of life (QoL) and fatigue respectively.
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| FODMAPs
Each patient filled out a 3-day food record in prior to the baseline meeting. Mean FODMAP content in the patients' diets were calculated by the Swedish database DietistNet. FODMAP content ≤9 g/ day was considered a low-FODMAP diet.
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| Statistical analysis
Statistical analysis was performed using GraphPad Prism version 
| RE SULTS
| Demographic and clinical data
Baseline characteristics are presented in Table 1 . Twenty-three patients were screened to participate in the study between February 2016 and January 2017. Two patients did not meet the inclusion criteria, thus they were not included. One patient withdrew after the baseline meeting. In total, 20 of the 23 screened patients completed the trial and were included in the study analysis (Figure 3) .
Of the twenty patients included, 14 were women. According to calculations based on a 3-day food record complemented by all the patients, the average daily intake of FODMAPs (n = 6). Two of twenty participants had elevated IgE for different food items, but the levels were low and they had no clinical symptoms of allergy or intolerance.
According to symptoms reported in IBS-SSS, IBS-SQ and the ad-
ditional GI questions at baseline the symptoms flatulence, belching and/or passing gas, interference with life in general and tiredness was listed as the major problems in the study group.
| Assessment of endpoints
When evaluating the symptom change during the provocation periods for the whole group using ANOVA analysis between baseline score (the first before-provocation measure), after-gluten score and after-placebo score, they showed the most severe symptoms When evaluating the symptom change during provocation in both groups using ANOVA analysis with Tukey's multiple comparison test, we found that the diagnosed group had a statistically significant increase in symptoms from baseline (13.3 ± 10.8) to after F I G U R E 3 Trial profile. The patients were randomly administered for gluten provocations (two periods) and placebo provocation (two periods). Each provocation period lasted for 4 days, with 3 days of wash-out before crossing over to the next round of provocation.
The distribution of the test material (Gluten=G/Placebo=P) was completely randomized, thus six different orders of distribution were possible: GPGP, PGPG, GGPP, PPGG, GPPG, and PGGP provocation with gluten (24.0 ± 6.6, P = .045) according to IBS-SQ sum score, but no statistically difference was seen between the gluten-and placebo-provocations, and the scores for after gluten (24.0 ± 6.6) and after placebo (24.4 ± 14.4) were numerically similar.
The symptom severity of abdominal pain was the only symptom with a statistically significant increase from baseline (28. 8 ± 19.3) to after gluten (57.5 ± 19.4, P = .028) for the diagnosed group when evaluating changes in the different symptoms reported. There was a significant increase from baseline to after placebo for the diagnosed group for the symptoms severity of abdominal distension (baseline: 37.5 ± 26.3, after placebo: 54.4 ± 23.8, P = .018) and flatulence (baseline: 4.0 ± 2.7, after placebo: 5.8 ± 2.7, P = .025).
The not-diagnosed group had a statistically significant increase in symptoms from baseline to after provocation with placebo according to both the IBS-SSS sum score (baseline: 154.6 ± 108.2, after placebo: 203.4 ± 98.8, P = .031) and the IBS-SQ sum score (baseline:
10.0 ± 12.4, after placebo: 15.9 ± 11.7, P = .032). They also showed a significantly higher score after placebo (203.4 ± 98.8) compared to after gluten (158.8 ± 109.3, P = .029) according to the IBS-SSS sum score ( Figure 5 ).
When evaluating change in the different symptoms reported in
the not-diagnosed group, we found that all symptoms had the numerically highest score after placebo, and the symptoms severity of abdominal pain (baseline: 16.6 ± 23.6, after placebo: 33.7 ± 26.7, P = .032), nausea (baseline: 1.1 ± 2.0, after placebo: 2.2 ± 2.3, P = .008) and diarrhea (baseline: 0.9 ± 1.8, after placebo: 2.6 ± 2.0, P = .022) had a statistically significant increase from baseline to after placebo.
| The effect of a low-FODMAP diet on symptom scores
We compared the participants eating a diet low in FODMAPs (n = 12) with those eating a diet containing what is regarded a normal FODMAP content (n = 8). Out of the four participants that were diagnosed, two were eating a low-FODMAP diet.
When evaluating symptom scores from the three implemented questionnaires, no clear association between FODMAP content in the participants' diets and gastrointestinal symptoms were seen either at baseline or during provocation, when comparing the low-FODMAP group with the normal-FODMAP group.
F I G U R E 4 Sum score for the implemented questionnaires, IBS-SSS (A), IBS-Q (B) and the additional GI questions (C)
, at baseline, after gluten provocation and after placebo for the group of patients with suspected NCGS (n = 20). Values are reported in mean (SD) and based on repeated measures one-way ANOVA supplemented with Tukey's multiple comparisons test. The symptom scores during provocation show no specific effect of gluten, but rather significant differences between the baseline and the placebo scores, indicating no effect of gluten in a group of patients with suspected NCGS, but more likely a nocebo reaction or a reaction to other substances in the patient's diet
F I G U R E 5 IBS-Symptom Severity
Score for the diagnosed group (A) and the not-diagnosed group (B) at baseline, after gluten provocation and after placebo. Values are reported as mean (SD) and based on repeated measures one-way ANOVA supplemented with Tukey's multiple comparisons test. No significant difference was found between placebo and gluten provocation in the diagnosed group, and for the not-diagnosed group the symptoms was statistically significant higher for placebo
| Quality of life
To evaluate whether the patient group with suspected NCGS in- . 16 This analysis showed that our patient group had significant higher score (21.3 ± 9.9) than the healthy control group at baseline (13.5 ± 7.0, P = .001), indicating that patients with suspected NCGS have reduced quality of life compared to a healthy population.
| Correlations
There were significant correlations between IBS-SSS sum score and baseline SF-NDI sum score (r = .76, P = .0001) and between IBS-SSS sum score and baseline FIS score (r = .63, P = .003), indicating that the severity of symptoms related to gastrointestinal afflictions correlated with reduced QoL and the severity of fatigue ( Figure 6 ).
The same significant positive correlations were also seen between the baseline IBS-SQ sum score and the baseline FIS score (r = .68, P = .001) and between the baseline IBS-SQ sum score and baseline SF-NDI sum score (r = .78, P = <.0001). This means that the severity of symptoms related to the participants' afflictions are of great influence of their QoL and the degree of fatigue.
| Carry-over-effect
The cross-over design in this study entails a potential carry-over- 
| D ISCUSS I ON
In the present study, we aimed to evaluate the effect of an oral gluten challenge as a diagnostic tool in patients with suspected NCGS.
Although four out of twenty patients correctly identified when they received gluten due to a self-experienced symptom relapse (hence were diagnosed with NCGS according to the current diagnostic guidelines), there was no statistically significant differences in symptom scores between the gluten-and the placebo-provocations to support this finding. Neither the diagnosed-group nor the group as a whole showed a specific symptomatic reaction to gluten when compared to the placebo exposures. Thus, according to our findings, a group of patients suspected to have NCGS did not show a specific reaction to provocation with gluten.
As highlighted in Figure 3 , no significant association between provocation material (gluten/placebo) and symptom severity was found when evaluating the symptom severity of the whole group.
The trend was that the group as a whole had overall higher scores after placebo than after provocation with gluten, indicating that most of the patients with suspected NCGS in fact did not react to ingestion of gluten. Anyhow, the patients did report unpleasant symptoms both at baseline, after gluten and after placebo, indicating that they do suffer from both intestinal and extraintestinal symptoms experienced as problematic. It is reasonable to believe that most patients with suspected NCGS do not react to gluten, but suffers from a functional gastrointestinal disorder that make them sensitive for different substances in the diet, in particular FODMAPs. Our findings clearly show that the majority of the group with a suspected reaction to gluten, cannot be correctly diagnosed as patients with NCGS.
Of the 20 study participants, four patients (20%) were diagnosed with NCGS according to the current standards for receiving a NCGS diagnosis. To receive a NCGS diagnosis, the patients had to correctly identify the two periods they were given gluten. The most important findings are the absence of difference between symptom scores during gluten-provocation and placebo in the group that received a diagnosis, indicating no specific effect of gluten. Although the diagnosed-group showed overall higher scores both at baseline,
Correlations between baseline sum score for IBS-SSS and SF-NDI (A) and between baseline sum score for IBS-SSS and FIS (B).
Values are reported in mean (SD)
after provocation with gluten and placebo than the not-diagnosed group according to all three questionnaires implemented, no clear differences were seen between the gluten provocation and placebo in the diagnosed-group.
The lack of difference between gluten and placebo provocation indicates that the correct identification of the gluten-containing muffins by the patients being diagnosed with NCGS could be by coincidence. The similarly high scores both after gluten and placebo indicate rather a nocebo effect. The fact that this subgroup was also the patient group reporting the most severe symptoms at baseline, while on a GFD, supports the assumption of a non-specific reaction, or a reaction to other substances in the food. However, the diag- studies. An analysis of 10 different DBPC gluten challenges found that only 16% of all suspected NCGS-patients included in such trials showed gluten-specific symptoms, and as many as 40% of these subjects experienced a nocebo response, seen as similar or higher symptoms in response to placebo. 21 The lack of control of confounding dietary factors such as total content of FODMAPs and ATIs in the participants' diets can be considered a weakness to the study. Our protocol did not make use of a standardized diet besides the GFD, thus the effect of other dietary variables cannot be excluded as a source of error. A dietary record could have been used during the study to assure that patients did not change their baseline diet.
The oral gluten provocation was performed using a standardized chocolate muffin mix. Similar studies have previously been performed using test material in the form of croissants, gastro-soluble capsules and flour to sprinkle over dinner, with an exposure of 5.6-16 g gluten per day. 10, 20, 22, 23 The patients in our trial consumed two muffins a day, equivalent to 11 g gluten. This amount of gluten is assumed to give adequate exposure to induce symptoms. Also, test material in the form of real food can arguably be more suitable than capsules, due to the physiological response.
1
The study was a DBPCFC, a design recognized as the gold standard in research on intolerances and allergies, and proposed as the preferred way of diagnosing NCGS. 11 Most previous similar studies have only implemented one cross-over with provocation periods lasting from one single day up to a week. [10] [11] [12] 20, 23 Hence, our study design with four provocation-periods of 4 days is considered to be an improvement relative to earlier protocols.
We chose to include 3 days of wash out (WO). It is hard to exclude that symptoms from the previous week will continue into the new week of provocation, making the evaluation of symptoms for the current week difficult. However, according to the knowledge on onset of symptoms (hours to days) it is likely to assume that if the symptoms were actually due to NCGS, the patients of current interest for receiving a diagnosis will be those managing to identify the gluten containing muffins regardless of overlapping symptoms. Previous similar studies have implemented from 3 to 14 days WO-period. 10, 12, 19, 20 The evaluation of symptom was made by the participants in the morning before eating the first muffin (baseline) and in the evening after the last day of provocation. This way of reporting symptoms can be a limitation, as the clinical experience shows that bloating in particular often gets worse in the evening and improves after a night of sleep. Assessing symptoms at different times of day could contribute to the increase in symptom scores from baseline to after provocation.
The mechanisms causing NCGS are unknown, and it is a subject of discussion whether gluten is at a problem for this group of patients. NCGS subjects are shown to be largely adherent to a strict GFD and many subjects are following a GFD without medical advice. 24, 25 Thus, further investigation of whether this strict adherence is necessary in this patient group is of great importance due to the knowledge of the GFD potentially not being nutritionally adequate.
A recent study investigated the diet and nutritional characteristics of patients with NCGS and found that these patients eat different foods than healthy individuals, and consumed lower levels of protein, carbohydrates, fiber, and polyunsaturated fatty acids, thus the diet of this patient group should be routinely analysed to avoid nutritional deficiencies.
26
It has been frequently hypothesized that NCGS cannot be separated from IBS as a unique diagnosis, but is rather presented as a sub-group of IBS. The amount of FODMAPs in the diet is most likely a contributor to symptoms in patients believing to have NCGS, and the relationship between NCGS and IBS needs to be investigated in further studies. According to the definition NCGS is a "syndrome characterized by intestinal and extra-intestinal symptoms related to ingestion of gluten-containing food, in subjects that are not affected by either CD or WA." 1 If this is the right definition it would be anticipated that removal of gluten alone from the diet would lead to a minimal of symptoms, and that reintroduction of gluten in the diet during provocation would trigger the symptoms. The results of our study do not support this concept.
In conclusion, the present study showed that the majority of patients with suspected NCGS are not able to identify when challenged with gluten in a DBPCFC, indicating that gluten is not the cause of their symptoms. Our findings are an important contribution to the debate regarding the existence of NCGS as a unique diagnosis, and support previous key DBPC trials pointing towards a more complex cause of symptoms than gluten sensitivity, with a high response to nocebo and lack of symptom reproducibility. Future studies investigating the cause of NCGS should aim to further evaluate the accumulative effect of FODMAPs in this group of patients and the relationship between the diagnosis of IBS and a reaction to cereals.
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